Latanoprost Patent Expiration
Latanoprost is Used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Upjohn Us 2 Llc
Latanoprost Patents
Given below is the list of patents protecting Latanoprost, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iyuzeh | US8637054 | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | Jul 08, 2031 | Thea Pharma |
| Xelpros | US9629852 | Ophthalmic composition comprising a prostaglandin | Sep 12, 2029 | Sun Pharm |
| Xelpros | US9539262 | Ophthalmic composition comprising a prostaglandin | Oct 15, 2028 | Sun Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Latanoprost's patents.
Latest Legal Activities on Latanoprost's Patents
Given below is the list recent legal activities going on the following patents of Latanoprost.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Oct, 2024 | US9629852 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539262 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2020 | US9629852 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2020 | US9539262 |
| Recordation of Patent Grant Mailed Critical
| 25 Apr, 2017 | US9629852 |
| Patent Issue Date Used in PTA Calculation Critical
| 25 Apr, 2017 | US9629852 |
| Email Notification Critical
| 06 Apr, 2017 | US9629852 |
| Issue Notification Mailed Critical
| 05 Apr, 2017 | US9629852 |
| Dispatch to FDC | 17 Mar, 2017 | US9629852 |
| Application Is Considered Ready for Issue Critical
| 16 Mar, 2017 | US9629852 |
Latanoprost's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Latanoprost:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) | University Hospital Dubrava | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2, PHASE3 |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | PolyActiva Pty Ltd | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension | Qlaris Bio, Inc. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2, PHASE3 |
| A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Santen Pharmaceutical Co., Ltd. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Alcon Research | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |